Sentinel Oncology is pleased to announce that it was recently awarded a feasibility grant as part of the government-backed Biomedical Catalyst initiative.
The project funded by the award is designed to assess the clinical significance of one of Sentinel's cancer drug discovery projects and identify the most appropriate cancer to treat in clinical studies. Sentinel Oncology has previously identified lead molecules which act as selective inhibitors of S6K, a key kinase in the PI3K pathway frequently implicated with tumour spread and metastasis.
Speaking about the award, Bob Boyle, Sentinel Oncology's CEO said 'We are delighted to receive this award as it will enable Sentinel Oncology to fund the sort of activities frequently passed over in the drug discovery phase in the search for new treatments for cancer. We are working with key academics in various different areas of cancer and expect to be able to identify the very best tumour type where our new drugs will have maximal effect in the clinic'
The Biomedical Catalyst, announced by Prime Minister David Cameron in December 2011, is a £180 million programme of public funding designed to deliver growth to the UK life sciences sector. Delivered jointly by the Medical Research Council and the Technology Strategy Board, the Biomedical Catalyst provides responsive and effective support for the best life science opportunities arising in the UK.